Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$203.66 USD
+2.83 (1.41%)
Updated Jul 19, 2024 04:00 PM ET
2-Buy of 5 2
F Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KRYS 203.66 +2.83(1.41%)
Will KRYS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KRYS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRYS
Krystal Biotech (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
KRYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
AstraZeneca's (AZN) Tagrisso sNDA Gets FDA's Priority Tag
Replimune (REPL) Gains on Positive Data From Melanoma Study
Other News for KRYS
Krystal Biotech participates in a conference call with Cantor Fitzgerald
Krystal Biotech participates in a conference call with Cantor Fitzgerald
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
TimesSquare Capital U.S. Small/Mid Cap Growth Q1 2024 Commentary